Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1993 Jun;67(6):3624–3629. doi: 10.1128/jvi.67.6.3624-3629.1993

Inhibition of retrovirus-induced disease in mice by camptothecin.

E Priel 1, E Aflalo 1, G Chechelnitsky 1, D Benharroch 1, M Aboud 1, S Segal 1
PMCID: PMC237713  PMID: 8388515

Abstract

We have previously shown that noncytotoxic doses of camptothecin (CPT), a topoisomerase I-specific antagonist, inhibit retrovirus replication in acutely and chronically infected cells. To evaluate the efficacy of CPT as an antiretroviral drug in vivo, we injected newborn BALB/c mice with Moloney murine leukemia virus and adult NFS mice with Friend spleen focus-forming virus. The Moloney murine leukemia virus-injected mice developed lymphoma, and the Friend spleen focus-forming virus-injected mice developed erythroleukemia. CPT, administrated together with the virus or 1 or 2 days after virus injection, prevented the onset of the disease in both cases. We showed that repeated CPT treatments increased the effectiveness of the drug when administrated 3 days after virus injection. This ability of CPT to inhibit retrovirus-induced disease in vivo without causing any apparent toxic side effects suggests its application as a legitimate remedy for the treatment of retroviral diseases.

Full text

PDF
3624

Images in this article

3626Image
on p.3626
3627Image
on p.3627

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5565–5569. doi: 10.1073/pnas.84.16.5565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. FRIEND C. Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med. 1957 Apr 1;105(4):307–318. doi: 10.1084/jem.105.4.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gallo R. C., Whang-Peng J., Adamson R. H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst. 1971 Apr;46(4):789–795. [PubMed] [Google Scholar]
  4. Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science. 1989 Nov 24;246(4933):1046–1048. doi: 10.1126/science.2555920. [DOI] [PubMed] [Google Scholar]
  5. Gottlieb J. A., Luce J. K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep. 1972 Feb;56(1):103–105. [PubMed] [Google Scholar]
  6. Gupta R. S., Gupta R., Eng B., Lock R. B., Ross W. E., Hertzberg R. P., Caranfa M. J., Johnson R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 1988 Nov 15;48(22):6404–6410. [PubMed] [Google Scholar]
  7. Heidmann T., Heidmann O., Nicolas J. F. An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2219–2223. doi: 10.1073/pnas.85.7.2219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Horwitz M. S., Horwitz S. B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem Biophys Res Commun. 1971 Nov 5;45(3):723–727. doi: 10.1016/0006-291x(71)90476-1. [DOI] [PubMed] [Google Scholar]
  9. Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25;260(27):14873–14878. [PubMed] [Google Scholar]
  10. Kabat D. Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol. 1989;148:1–42. doi: 10.1007/978-3-642-74700-7_1. [DOI] [PubMed] [Google Scholar]
  11. Kaufmann S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989 Nov 1;49(21):5870–5878. [PubMed] [Google Scholar]
  12. Lee J. C., Ihle J. N. Chronic immune stimulation is required for Moloney leukaemia virus-induced lymphomas. Nature. 1981 Jan 29;289(5796):407–409. doi: 10.1038/289407a0. [DOI] [PubMed] [Google Scholar]
  13. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  14. Moertel C. G., Schutt A. J., Reitemeier R. J., Hahn R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 1972 Feb;56(1):95–101. [PubMed] [Google Scholar]
  15. Muggia F. M., Creaven P. J., Hansen H. H., Cohen M. H., Selawry O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep. 1972 Aug;56(4):515–521. [PubMed] [Google Scholar]
  16. Priel E., Showalter S. D., Blair D. G. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses. 1991 Jan;7(1):65–72. doi: 10.1089/aid.1991.7.65. [DOI] [PubMed] [Google Scholar]
  17. Priel E., Showalter S. D., Roberts M., Oroszlan S., Blair D. G. The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells. J Virol. 1991 Aug;65(8):4137–4141. doi: 10.1128/jvi.65.8.4137-4141.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Priel E., Showalter S. D., Roberts M., Oroszlan S., Segal S., Aboud M., Blair D. G. Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. EMBO J. 1990 Dec;9(12):4167–4172. doi: 10.1002/j.1460-2075.1990.tb07640.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rowe W. P., Pugh W. E., Hartley J. W. Plaque assay techniques for murine leukemia viruses. Virology. 1970 Dec;42(4):1136–1139. doi: 10.1016/0042-6822(70)90362-4. [DOI] [PubMed] [Google Scholar]
  20. Schaeppi U., Fleischman R. W., Cooney D. A. Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 3. 1974 Sep;5(1):25–36. [PubMed] [Google Scholar]
  21. Spataro A., Kessel D. Studies on camptothecin-induced degradation and apparent reaggregation of DNA from L1210 cells. Biochem Biophys Res Commun. 1972 Aug 7;48(3):643–648. doi: 10.1016/0006-291x(72)90396-8. [DOI] [PubMed] [Google Scholar]
  22. Wolfe J. H., Hardy W. D., Jr Immunogenetics of murine and feline retroviruses. Immunol Ser. 1989;43:561–595. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES